S S Dharap
Overview
Explore the profile of S S Dharap including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
4
Citations
208
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Dharap S, Wang Y, Chandna P, Khandare J, Qiu B, Gunaseelan S, et al.
Proc Natl Acad Sci U S A
. 2005 Aug;
102(36):12962-7.
PMID: 16123131
The central problem in cancer chemotherapy is the severe toxic side effects of anticancer drugs on healthy tissues. Invariably the side effects impose dose reduction, treatment delay, or discontinuance of...
2.
Minko T, Dharap S, Pakunlu R, Wang Y
Curr Drug Targets
. 2004 May;
5(4):389-406.
PMID: 15134222
This review presents molecular targeting approaches in anticancer drug delivery systems (DDS) and identifies new developments in these systems. Targeting approaches include passive targeting (enhanced permeability and retention effect), targeting...
3.
Dharap S, Qiu B, Williams G, Sinko P, Stein S, Minko T
J Control Release
. 2003 Aug;
91(1-2):61-73.
PMID: 12932638
Novel targeted proapoptotic anticancer drug delivery systems were developed and evaluated. Poly(ethyleneglycol) (PEG) conjugates were used as carriers. Camptothecin (CPT) was used as an anticancer agent-apoptosis inductor. Two types of...
4.
Minko T, Dharap S, Fabbricatore A
Cancer Detect Prev
. 2003 Jun;
27(3):193-202.
PMID: 12787726
The study was aimed at evaluating the combination of a traditional anticancer drug doxorubicin (DOX) with a suppressor of antiapoptotic cellular defense--synthetic peptide corresponding to the minimal sequence of BCL-2...